

招股概略

上海复宏汉霖生物技术股份有限公司 (2696)

发行数据

集资额:	3,208.9 –3,739.4 百万港元
发售股份数目:	64,695,400 股 H 股
价格:	49.60 –57.80 港元
每手股数:	100
入场费:	5,838.25 港元
历史市盈率:	不适用
每股有形资产净值:	6.09 –7.04 港元
市值(招股后):	7,889.5 –9,193.8 百万港元
招股开始:	2019 年 9 月 12 日
招股截止:	2019 年 9 月 17 日中午 12 时
上市:	2019 年 9 月 25 日
保荐人:	中国国际金融香港证券有限公司、Merrill Lynch Far East Limited、招银国际融资有限公司、复星恒利证券有限公司及花旗环球金融亚洲有限公司

12 月 31 日止年度	人民币千元	按年变动
来自持续经营业务的收入		
2017 年	33,910	N/A
2018 年	7,421	-78.1%
年内 / 期间利润		
2017 年	-384,327	N/A
2018 年	-504,789	31.3%

背景

- 集团是一家中国领先的生物制药公司，旨在为全球患者提供质高价优的创新药物。
- 集团是首家根据现行中国有关生物类似药评价及上市审批的法规《生物类似药指导原则》，就单克隆抗体生物类似药自国家药监局取得新药药证申请批准的生物制药公司，且亦为中国首家商业化推出生物类似药产品的生物制药公司。
- 于最后实际可行日期，除集团已商业化推出的生物类似药产品（即 HLX01 汉利康）外，集团在管线中自主开发 20 种以上候选生物药及多种肿瘤免疫联合疗法，其中
  - 两种候选单抗获国家药监局接纳新药药证申请，包括一种候选单抗获欧洲药品管理局接纳营销授权申请；
  - 两种候选单抗正在进行 3 期临床试验及六种候选单抗正在进行 1/2 期临床试验，以及两种肿瘤免疫联合疗法正在进行 3 期临床试验；及
  - 已在不同司法权区取得 31 项新药临床试验申请批准。

业务策略

- 进一步巩固集团在生物类似药持续开发方面的领导地位，并把握先发优势；
- 利用集团强大而全面的生物药物管线及成熟的单抗开发平台，开发以肿瘤免疫联合疗法为主的创新产品组合；
- 在维持高质量标准的同时扩大产能及提高成本效益；
- 通过内部销售及市场团队及合作伙伴关系提升商业化能力；及
- 选择性地进行战略合作，以扩大集团的全球版图。

### 竞争优势

- 具有吸引力的商业模式：兼备近期可实现性及长期增长性；
- 高效的一体化全球研发平台，开发出强大的产品管线；
- 具有加强成本效益和健全质量管理体系的大规模生产能力；
- 强大的全球商业化能力；及
- 远见卓识的联合创始人及领导团队。

### 主要风险

- 与集团的财务前景及额外资金需求有关的风险；
- 与集团候选药物开发、临床试验及监管批准有关的风险；
- 与集团的候选药物商业化有关的风险；
- 与知识产权有关的风险；
- 与集团的经营有关的风险；
- 与在中国经营业务有关的风险；及
- 与全球发售有关的风险

### 股息政策

- 无固定股息政策。

### 所得款项用途

	(百万港元)	比重
将用于拨付持续进行的核心产品的临床试验、监管备案及注册	1,341.7	40.0%
将用于拨付持续进行的候选生物类似药（包括 HLX12、HLX11 及 HLX14）的临床试验、监管备案及注册	503.1	15.0%
将用于拨付持续进行的生物创新药的临床试验、监管备案及注册以及开发免疫肿瘤联合疗法	1,174.0	35.0%
将分配至营运资金及一般企业用途	335.4	10.0%
<b>合计：</b>	<b>3,354.1</b>	<b>100.0%</b>

## Disclosures/Disclaimers

This report is prepared by UOB Kay Hian (Hong Kong) Limited (“UOBKHHK”), which is a licensed corporation providing securities brokerage and securities advisory services in Hong Kong.

This report is provided for information only and is not an offer or a solicitation to deal in securities or to enter into any legal relations, nor an advice or a recommendation with respect to such securities.

**This report is prepared for general circulation.** It does not have regard to the specific investment objectives, financial situation and the particular needs of any recipient hereof. Advice should be sought from a financial adviser regarding the suitability of the investment product, taking into account the specific investment objectives, financial situation or particular needs of any person in receipt of the recommendation, before the person makes a commitment to purchase the investment product.

This report is confidential. This report may not be published, circulated, reproduced or distributed in whole or in part by any recipient of this report to any other person without the prior written consent of UOBKHHK. This report is not directed to or intended for distribution to or use by any person or any entity who is a citizen or resident of or located in any locality, state, country or any other jurisdiction as UOBKHHK may determine in its absolute discretion, where the distribution, publication, availability or use of this report would be contrary to applicable law or would subject UOBKHHK and its associates (as defined in the Securities and Futures Ordinance, Chapter 571 of Hong Kong) to any registration, licensing or other requirements within such jurisdiction.

The information or views in the report (“Information”) has been obtained or derived from sources believed by UOBKHHK to be reliable. However, UOBKHHK makes no representation as to the accuracy or completeness of such sources or the Information and UOBKHHK accepts no liability whatsoever for any loss or damage arising from the use of or reliance on the Information. UOBKHHK and its associates may have issued other reports expressing views different from the Information and all views expressed in all reports of UOBKHHK and its associates are subject to change without notice. UOBKHHK reserves the right to act upon or use the Information at any time, including before its publication herein.

Except as otherwise indicated below, (1) UOBKHHK, its associates and its officers, employees and representatives may, to the extent permitted by law, transact with, perform or provide broking, underwriting, corporate finance-related or other services for or solicit business from, the subject corporation(s) referred to in this report; (2) UOBKHHK, its associate and its officers, employees and representatives may also, to the extent permitted by law, transact with, perform or provide broking or other services for or solicit business from, other persons in respect of dealings in the securities referred to in this report or other investments related thereto; (3) the officers, employees and representatives of UOBKHHK may also serve on the board of directors or in trustee positions with the subject corporation(s) referred to in this report. (All of the foregoing is hereafter referred to as the “Subject Business”); and (4) UOBKHHK may otherwise have an interest (including a proprietary interest) in the subject corporation(s) referred to in this report.

As of the date of this report, no analyst responsible for any of the content in this report has any proprietary position or material interest in the securities of the corporation(s) which are referred to in the content they respectively author or are otherwise responsible for.

### IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report is prepared by UOBKHHK, a company authorized, as noted above, to engage in securities activities in Hong Kong. UOBKHHK is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution by UOBKHHK (whether directly or through its US registered broker dealer affiliate named below) to “major U.S. institutional investors” in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”). All US persons that receive this document by way of distribution from or which they regard as being from UOBKHHK by their acceptance thereof represent and agree that they are a major institutional investor and understand the risks involved in executing transactions in securities.

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through UOB Kay Hian (U.S.) Inc (“UOBKHUS”), a registered broker-dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through UOBKHHK.

UOBKHUS accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to and intended to be received by a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority (“FINRA”) and may not be an associated person of UOBKHUS and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

### Analyst Certification/Regulation AC

Each research analyst of UOBKHHK who produced this report hereby certifies that (1) the views expressed in this report accurately reflect his/her personal views about all of the subject corporation(s) and securities in this report; (2) the report was produced independently by him/her; (3) he/she does not carry out, whether for himself/herself or on behalf of UOBKHHK or any other person, any of the Subject Business involving any of the subject corporation(s) or securities referred to in this report; and (4) he/she has not received and will not receive any compensation that is directly or indirectly related or linked to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. However, the compensation received by each such research analyst is based upon various factors, including UOBKHHK's total revenues, a portion of which are generated from UOBKHHK's business of dealing in securities.

Reports are distributed in the respective countries by the respective entities and are subject to the additional restrictions listed in the following table.

General	This report is not intended for distribution, publication to or use by any person or entity who is a citizen or resident of or located in any country or jurisdiction where the distribution, publication or use of this report would be contrary to applicable law or regulation.
Hong Kong	This report is distributed in Hong Kong by UOB Kay Hian (Hong Kong) Limited ("UOBKHHK"), which is regulated by the Securities and Futures Commission of Hong Kong. Neither the analyst(s) preparing this report nor his associate, has trading and financial interest and relevant relationship specified under Para. 16.4 of Code of Conduct in the listed corporation covered in this report. UOBKHHK does not have financial interests and business relationship specified under Para. 16.5 of Code of Conduct with the listed corporation covered in this report. Where the report is distributed in Hong Kong and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKHHK (and not the relevant foreign research house) in Hong Kong in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Hong Kong who is not a professional investor, or institutional investor, UOBKHHK accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Indonesia	This report is distributed in Indonesia by PT UOB Kay Hian Securities, which is regulated by Financial Services Authority of Indonesia (OJK). Where the report is distributed in Indonesia and contains research analyses or reports from a foreign research house, please note recipients of the analyses or reports are to contact PT UOBKH (and not the relevant foreign research house) in Indonesia in respect of any matters arising from, or in connection with, the analysis or report.
Malaysia	Where the report is distributed in Malaysia and contains research analyses or reports from a foreign research house, the recipients of the analyses or reports are to contact UOBKHM (and not the relevant foreign research house) in Malaysia, at +603-21471988, in respect of any matters arising from, or in connection with, the analysis or report as UOBKHM is the registered person under CMSA to distribute any research analyses in Malaysia.
Singapore	This report is distributed in Singapore by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser regulated by the Monetary Authority of Singapore. Where the report is distributed in Singapore and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKH (and not the relevant foreign research house) in Singapore in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, UOBKH accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Thailand	This report is distributed in Thailand by UOB Kay Hian Securities (Thailand) Public Company Limited, which is regulated by the Securities and Exchange Commission of Thailand.
United Kingdom	This report is being distributed in the UK by UOB Kay Hian (U.K.) Limited, which is an authorised person in the meaning of the Financial Services and Markets Act and is regulated by The Financial Conduct Authority. Research distributed in the UK is intended only for institutional clients.
United States of America ('U.S.')	This report cannot be distributed into the U.S. or to any U.S. person or entity except in compliance with applicable U.S. laws and regulations. It is being distributed in the U.S. by UOB Kay Hian (US) Inc, which accepts responsibility for its contents. Any U.S. person or entity receiving this report and wishing to effect transactions in any securities referred to in the report should contact UOB Kay Hian (US) Inc. directly.